Last updated on July 2017

A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients


Brief description of study

The study will assess the safety, tolerability and efficacy of CSJ137 in chronic hemodialysis patients. It is hypothesized that treatment with CSJ137 may improve the level of hemoglobin in patients on chronic hemodialysis with iron-restricted anemia while reducing the need for dosing with erythropoietin and intravenous iron in these patients.

Detailed Study Description

This posting discloses information about Part 1 of CCSJ137X2201. Another part, Part 2, of this trial is planned for conduct subsequent to the initiation of Part 1 and will have a different design than Part 1. The details of the design for this additional part are planned for disclosure in advance of conduct of Part 2.

Clinical Study Identifier: NCT02570854

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Novartis Pharmaceuticals

Novartis Investigative Site
Lakewood, CO United States
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Orlando, FL United States
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Minneapolis, MN United States
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Chattanooga, TN United States
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Ashkelon, Israel
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Jerusalem, Israel
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Petach Tikva, Israel
  Connect »